VNU, IMS look for way out of deal: WSJ

Share this article:
Dutch publishing giant VNU is locked in a stalemate with U.S. pharmaceutical research company IMS Health over how to terminate its $7 billion planned acquisition of IMS, The Wall Street Journal reported today.
Holders of nearly half of VNU's shares have said they would turn down the plan to buy IMS, forcing VNU to find a way to abandon its agreed purchase of IMS.
After holding talks, the two companies can't agree on terms to end the deal, the newspaper reported.
VNU said early today that it is "having wide ranging discussions with IMS" to address the development.
In a statement, VNU said that "although both companies continue to believe the transaction, as negotiated, is in the best interests of their respective shareholders, the companies have discussed various possible alternatives, including a revised merger agreement as well as termination of the agreement."
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.